Nama's AI scorecard currently rates GeneDx Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is WGS's P/E ratio?

GeneDx trades at a trailing price-to-earnings ratio of 173.2.

When does WGS report earnings?

GeneDx's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $0.07.

What is the WGS price target?

The median analyst price target from 8 analysts is $92.50, with a range of $83.00 – $103.00.

Is WGS Shariah compliant?

Nama's AAOIFI-style screen reads GeneDx as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

GeneDx (WGS)

Healthcare · Diagnostics Research · NASDAQ

GeneDx (WGS) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $1.86B, a trailing price-to-earnings ratio of 173.2 and a free-cash-flow yield of 0.8%. Over the most recent reported fiscal year, revenue grew 40.0%. Nama's AI scorecard rates it Sell, 3.4 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Sell · 3.4/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Trailing · -50.6% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-78.5%

How far the last close sits under the highest price of the past five years.

Market cap	$1.86B
Trailing P/E	173.2
Price / book	7.6
Price / sales	4.1
FCF yield	0.8%
Dividend yield	—
Gross margin	69.4%
Operating margin	-13.0%
Net margin	-23.4%
Revenue growth (YoY)	+40.0%
Revenue growth (3-yr annual)	+22.1%
EPS growth (YoY)	+460.0%
FCF/share growth (YoY)	—
Beta	2.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Diagnostics Research

WGS earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate $0.07). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 3, 2026	$0.01	-$0.19	+105.3%	$114.44M
Q1 2026	May 4, 2026	-$0.28	-$0.02	-1300.0%	$102.25M
Q4 2025	Feb 23, 2026	$0.14	$0.12	+16.7%	$120.99M
Q3 2025	Oct 28, 2025	$0.49	$0.42	+16.7%	$116.74M

WGS analyst price target

Median target $92.50 from 8 analysts, ranging $83.00 – $103.00.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
IDXX	IDEXX Laboratories	$53.26B	45.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
IQV	IQVIA	$44.80B	21.2
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2

Explore live WGS data on Nama Insights →

WGS FAQ

Is WGS a buy?: Nama's AI scorecard currently rates GeneDx Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is WGS's P/E ratio?: GeneDx trades at a trailing price-to-earnings ratio of 173.2.
When does WGS report earnings?: GeneDx's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $0.07.
What is the WGS price target?: The median analyst price target from 8 analysts is $92.50, with a range of $83.00 – $103.00.
Is WGS Shariah compliant?: Nama's AAOIFI-style screen reads GeneDx as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.